Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
09:15am, Tuesday, 20'th Feb 2024
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.28 per share a year ago.
Why Axsome (AXSM) Might Surprise This Earnings Season
10:01am, Thursday, 15'th Feb 2024
Axsome (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Tuesday, 13'th Feb 2024
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 Stocks That Could Double Your Money in 5 Years
07:45am, Thursday, 08'th Feb 2024
Shopify and Axsome Therapeutics have crushed the market in the past five years. Thanks to a recent strategic move, Shopify's top and bottom lines should improve.
5 medical stocks growing earnings by triple digits
10:46am, Tuesday, 06'th Feb 2024
While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Thursday, 25'th Jan 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
07:00am, Tuesday, 23'rd Jan 2024
NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
12:02pm, Friday, 05'th Jan 2024
Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates.
Axsome (AXSM) Surges 7.8%: Is This an Indication of Further Gains?
09:46am, Friday, 05'th Jan 2024
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
2 Biotech Stocks You Can Buy and Hold for the Next Decade
08:45am, Tuesday, 02'nd Jan 2024
AbbVie's recent major patent cliff won't kill its returns throughout the next decade. Axsome Therapeutics is gaining in prominence thanks to an exciting late-stage pipeline.
Axsome: Show Me Another Company With Such A Stack Of Catalysts
09:28am, Sunday, 24'th Dec 2023
Axsome Therapeutics has consistently beaten revenue estimates since the approval of Auvelity, indicating better-than-expected performance. While the company's expenses, particularly in commercial acti
3 Biotech Stocks That Could Be Millionaire Makers
05:30am, Wednesday, 22'nd Nov 2023
There are several paths to millionaire status, and investing is one of them. But to give yourself a chance to become a millionaire this way, it's important to buy a diverse basket of solid companies a
3 Growth Stocks to Buy Right Now Without Any Hesitation
06:50am, Saturday, 11'th Nov 2023
AbbVie looks like a bargain that has stronger growth on the way. Axsome Therapeutics is in the early innings of what could be an exciting growth story.
Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates
12:47pm, Tuesday, 07'th Nov 2023
Axsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement.
Riding the Wave: 3 Stocks That Can 10X by 2025
09:23pm, Monday, 30'th Oct 2023
It's the dream of every investor to uncover stocks with the potential to grow tenfold within a short span. While it may sound like a lofty goal, the article reveals that it's not just a pipe dream.
